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Abstract Aneurysm of the abdominal aorta (AAA) is a particular, specifically localized form of atherothrombosis, providing a
unique human model of this disease. The pathogenesis of AAA is characterized by a breakdown of the extracellular
matrix due to an excessive proteolytic activity, leading to potential arterial wall rupture. The roles of matrix metal-
loproteinases and plasmin generation in progression of AAA have been demonstrated both in animal models and in
clinical studies. In the present review, we highlight recent studies addressing the role of the haemoglobin-rich, intra-
luminal thrombus and the adventitial response in the development of human AAA. The intraluminal thrombus exerts
its pathogenic effect through platelet activation, fibrin formation, binding of plasminogen and its activators, and trap-
ping of erythrocytes and neutrophils, leading to oxidative and proteolytic injury of the arterial wall. These events
occur mainly at the intraluminal thrombus–circulating blood interface, and pathological mediators are conveyed out-
wards, where they promote matrix degradation of the arterial wall. In response, neo-angiogenesis, phagocytosis by
mononuclear cells, and a shift from innate to adaptive immunity in the adventitia are observed. Abdominal aortic
aneurysm thus represents an accessible spatiotemporal model of human atherothrombotic progression towards clini-
cal events, the study of which should allow further understanding of its pathogenesis and the translation of pathogenic
biological activities into diagnostic and therapeutic applications.
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1. Introduction
The initial definition of aneurysms was morphological, as a focal loss of
parallelism of the vascular wall, leading to progressive dilatation and
finally to rupture.1 This definition can be now challenged by the fol-
lowing pathophysiological definition: the progressive loss in the
capacity to resist high intraluminal pressure, related to the degradation
of the arterial wall. Since aneurysms of the abdominal aorta (AAAs)
are usually asymptomatic, the present clinical challenge is to diagnose
them at an early stage, and to decipher the biological mechanisms
responsible for the progressive dilatation and final rupture, in order
to develop new diagnostic and therapeutic approaches.
2. Epidemiology
Aneurysms of the abdominal aorta develop mainly in men over
65 years old, in whom the frequency reaches 1–5%. Progression of
AAAs towards rupture is not linear, but usually presents points of
acceleration which can appear at any time.2,3 Conversely, aortic dila-
tations can remain stable and asymptomatic for many years, during
which aged patients may die of other causes.4 In women, AAAs are
rarer, but represent a higher relative mortality than men.5 When com-
paring men and women with AAA, it was found, using gender-specific
criteria for normal aortic diameters, that women had a significantly
higher risk of associated thoracic aneurysms.6
* Corresponding author. Tel: +33 1 40 25 86 00, Fax: +33 1 40 25 86 02, Email: jean-baptiste.michel@inserm.fr
† The ‘Fighting Aneurysmal Disease’ (FAD, #217) European integrated project (Health-F2-2008-200647), http://www.fighting-aneurysm.org/
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2010. For permissions please email: journals.permissions@oxfordjournals.org.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-
commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of
publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated.
For commercial re-use, please contact journals.permissions@oxfordjournals.org.
Cardiovascular Research (2011) 90, 18–27
doi:10.1093/cvr/cvq337
3. Impact of screening programmes
Abdominal aortic aneurysm includes an asymptomatic phase with a
relatively low risk, which is amenable to screening. Ultrasonographic
screening is a valid, suitable, and acceptable method, which is sensitive
(98%) and specific (99%). Persons at the highest risk of AAA attend
screening more frequently than persons at low risk,7 and repeated
screening is only required in 5% of the initially negative cases.8
Evidence-based large-scale randomized trials have identified 5.5 cm
diameter as the cut-off point for repairing asymptomatic AAA,9 and
survivors enjoy the same quality of life as the general population of
the same age. Only about 2–5% of patients refuse an offer of surgery.
The benefits of screening must outweigh the costs. All four existing
randomized trials report benefit of screening of men aged 65 years
and older, and the pooled mid- and long-term relative risk reduction
is around 50%.10 Cost effectiveness has proven attractive,11 and
recently the Viborg Study reported that the number required to be
screened to save one life was only 135, and the frequency of emer-
gency operations due to rupture was reduced by 56%.12 In all, offering
men aged 65–74 years screening for AAA seems acceptable accord-
ing to criteria from the European Council, but nationwide implemen-
tation in Europe is only ongoing in the UK.12
4. Environmental risk factors
Abdominal aortic aneurysm is a particular, specifically localized form
of atherothrombotic disease, sharing the usual risk factors with occlu-
sive atherothrombosis, as follows: male sex, ageing, possible genetic
susceptibility and dyslipidaemia. Ageing influences AAA development
through the observed progressive physiological enlargement of the
aorta and the increase in pulse wave reflection linked to aortic rigidi-
fication. Peripheral arterial diameter is generally larger in AAA
patients compared with age- and sex-matched control subjects.13
Smoking is the major risk factor in AAA, probably linked to its
ability to oxidize a1-antitrypsin. Therefore, plasma nicotine could
be used for monitoring smoking in AAA patients.14 Among lipid
markers, low high-density lipoprotein level is the most sensitive pre-
dictor of AAA.15 This could be related to the impact of hypercholes-
terolaemia on the initial step of atheroma in the aorta, and to the low
levels of a1-antitrypsin conveyed by high-density lipoprotein in human
AAA.16 In contrast to occlusive atheroma, diabetes is not a risk factor,
probably due to glycation of extracellular matrix molecules, which
increases their resistance to proteolysis.17 The presence of AAA in
a patient is a marker of atherothrombotic disease elsewhere,18 and
aortic diameter a predictor of total and cardiovascular mortality.19
4.1 Genetic susceptibility
Genetic determinants of susceptibility to AAA have been approached
through investigation of familial aggregation of the disease, and more
recently by genomewide association studies in populations. The fre-
quency of AAA in first-order relatives was 15–19%, whereas it was
only 1–3% in unrelated patients. Numerous associations between
AAA growth and polymorphisms in different target genes have
been explored (see20 for review). In a nationwide register study,
the relative risk of developing an AAA was approximately doubled
for individuals with a first-degree relative with AAA.6 A subsequent
study based on the Swedish twin register showed an increased risk
for a dizygotic twin when the other one had an AAA compared
with the previous nationwide study, and the odds ratio was 10-fold
higher for a monozygotic twin of an AAA patient compared with a
dizygotic twin.21 Moreover, the monozygotic twin of an AAA
patient had a risk of developing an AAA that was 71 times higher
than the monozygotic twin of an unaffected person.21
Recently, using genomewide association studies, a common
sequence variant, first described to be strongly associated with coron-
ary artery disease, was reported to be associated with human AAA
and intracranial aneurysms in several populations.22 This variant,
rs10757278, resides at a locus on chromosome 9p21 adjacent to
the genes CDKN2A/CDKN2B, which are important regulators of cell
growth and survival. An additional common sequence variant associ-
ating with AAA, situated on chromosome 9q33, has since been
reported and is also associated with myocardial infarction, peripheral
arterial disease, and pulmonary embolism, but not with intracranial
aneurysms. This AAA risk variant was independent of smoking, lipid
levels, obesity, diabetes, and hypertension, and is located within the
DAB2IP gene that encodes an inhibitor of cell growth and survival.
This is the second common variant that consistently associates with
AAA in multiple populations.23
5. Pathophysiology of AAA, a
spatiotemporal model of proteolytic
atherothrombosis
Aneurysms of the abdominal aorta are a particular form of athero-
thrombosis, in which the pathogenic role of proteolysis is predomi-
nant.1 The main role of proteases, including matrix
metalloproteinases (MMPs) and serine proteases, in the evolution of
AAA was first put forward 30 years ago in human studies.24 Com-
pared with the occlusive forms of atherothrombosis, involving necro-
tic core formation in the intima, AAA is characterized by its
localization in the matrix-rich aortic media, the presence of a
chronic intraluminal thrombus (ILT), and the association with a signifi-
cant adventitial reaction.25
5.1 Convection and spatial organization
Physiological transport in the aortic wall occurs mainly by orthogonal
hydraulic conductance from the lumen to the adventitia through the
arterial wall. This centrifugal convection is dependent on blood
pressure, low shear rate, and the filtration properties of the arterial
wall.26 Such convection is probably greatly enhanced at the site of
AAA due to the high porosity of the ILT,27 the lack of endothelium,28
medial elastic fibre degradation,29 low shear due to recirculation in
vortices,30 and high amplitude of pulsatility due to dilatation.31 More-
over, the ILT does not decrease wall stress in AAA.32 The pathogenic
mediators, generated at the blood–ILT interface, are thus centrifugally
conveyed towards the media and the adventitia in AAA. The structure
of AAAs is usually spatially organized, from inside to out, with a multi-
layered, haemoglobin-rich ILT, a thin degraded media in which the
elastic components have more or less disappeared, and an inflamma-
tory and/or fibrotic adventitia. Due to the presence of the ILT, there is
no endothelium or intima in AAAs.
5.2 Haemoglobin-rich ILT
The ILT is a biologically active neo-tissue described as a laminated
structure, containing several layers of fibrin clot, underlying a fresh,
red haematic luminal layer containing undegraded cross-linked fibrin,
and an actively fibrinolysed abluminal layer (Figure 1). This observation
Pathophysiology of abdominal aortic aneurysms 19
supports the hypothesis of a dynamic biological equilibrium between
clotting at the luminal interface with circulating blood and outward
progressive lysis, providing evidence of a spatial topology of temporal
events (clotting and lysis). The ILT is traversed from the luminal to the
abluminal surface by a continuous network of canaliculi, allowing
unrestricted macromolecular penetration.27
The luminal layer is highly biologically active, characterized by red
blood cell (RBC) haemagglutination, a process that releases free hae-
moglobin, and fibrin formation secondary to platelet and thrombin
activation. It is also responsible for tissue-plasminogen activator and
plasminogen retention33 involved in the postponed progressive fibri-
nolysis,34 and lastly for leucocyte retention, in which neutrophils pre-
dominate. The intermediate and abluminal layers are less rich in
blood-borne components.
There is now evidence that ILTs participate in aneurysmal dilatation,
regardless of localization, i.e. abdominal35 and thoracic aorta36 and
intracranial aneurysms.37 The presence of an ILT has been shown to
be associated with a thinner arterial wall,38 more extensive elastolysis,
a lower density of smooth muscle cells in the media, and a higher level
of immuno-inflammation in the adventitia,39 suggesting that an impor-
tant part of the protease activity originates from the ILT, rather than
being directly generated within the AAA wall.
The biological activities generated by the blood interface first
involve platelet activation, which releases microparticles and
exposes phospholipids.40 Haemagglutination of RBCs is also an impor-
tant activity associated with the blood interface, and RBCs are usually
rapidly degraded in the subjacent layer, releasing free haemoglobin,
which is a powerful pro-oxidant mediator due to its haem/iron com-
ponent (see41 for review). In parallel, the globin component under-
goes proteolytic degradation, generating specific peptides.42 The
haem group is able to engage chemical reactions that result in the gen-
eration of free radicals,41 and oxidative stress is involved in AAA
pathogenesis (see43 for review), through its ability to damage subja-
cent tissue.
Enhanced activity of oxidant enzymes and/or reduced activity of
antioxidant chelators lead to oxidative stress. Myeloperoxidase,
NADPH oxidase, and catalysis by iron have been described in
human AAA. However, lipoxygenase and leukotriene hydrolase44
could also participate. In relation to this dysregulation, antioxidant
enzymes, superoxide dismutase, glutathione peroxidise, and gluta-
thione reductase activities were reduced in AAA tissue compared
with non-diseased aorta.45,46 In an experimental model of AAA, cat-
alase supplementation inhibited aneurysm formation.47 Thioredoxin
is released from cells in response to oxidative stress,48 and increased
thioredoxin levels have been recently reported in the conditioned
medium of ILT.49 Moreover, circulating thioredoxin levels were corre-
lated with AAA size and growth, highlighting the importance of oxi-
dative stress.
The in vivo formation of fibrin is always associated with the reten-
tion of plasminogen and tissue-plasminogen activator, due to the bio-
chemical ability of these two proteins to bind to free lysine residues
present in the fibrin polymer. The process of fibrinolysis is postponed
Figure 1 Biological features of the intraluminal thrombus (ILT). (A) Macroscopic view showing the red, most recent, luminal layer of the ILT and the
abluminal proteolysed layer. (B) Microscopic aspect of the luminal layer including trapped red blood cells and a large area of nucleated, cell-rich fibrin
(haematoxylin and eosin, ×4). (C) Immunostaining of platelet glycoprotein Ib on the luminal ILT surface (×4). (D) Immunostaining of neutrophils
(CD66b) on the luminal surface (×4).
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in vitro and in vivo to reinforce coagulation. In AAA, the initial retention
of plasminogen and tissue-plasminogen activator from plasma, and
urokinase-type plasminogen activator (u-PA), conveyed by neutro-
phils, together with some of their inhibitors, takes place in the most
luminal ILT layer.33 However, active fibrinolysis is spatially and tem-
porarily delayed, and the release of fibrin degradation products
increases from the inner to the outer ILT layers.34 The strongest fibri-
nolytic activity is present at the abluminal interface between the ILT and
the wall.34 Besides its ability to proteolyse fibrin, plasmin is able to acti-
vate MMPs, mobilize transforming growth factor-b from its extracellu-
lar matrix storage site, and degrade adhesive pericellular proteins, such
as fibronectin, inducing mesenchymal cell detachment and death.50
Neutrophils are 12 times more numerous in clots than in circulating
blood because these cells have a high affinity for the fibrin–fibronec-
tin network, via integrins,51 and bind to platelet-exposed P-selectin via
the expression of the sialyl Lewis-X-containing polysaccharidic
ligand.52 Neutrophils are terminally differentiated cells, which
undergo constitutive apoptosis after binding. Localization of neutro-
phils in the luminal part of the thrombus is associated with increased
level of MMP-8, MMP-9,40 and elastase compared with other layers.53
Neutrophils could enhance both coagulation and fibrinolysis, because
elastase can cleave tissue factor plasma inhibitor54 and fibrin.55
Leucocytes release granular serine proteases, such as u-PA, elas-
tase, proteinase 3, and cathepsins (major components of the azuro-
philic granules), MMP-9 and MMP-8 (gelatinase granules), and
pro-oxidant activities, such as NADPH oxidase and myeloperoxidase.
The ILT is particularly rich in pro- and active forms of MMP-9,56 and
MMP-9–lipocalin complexes are of neutrophil origin.57 Neutrophil
proteases can degrade all matrix fibrillar proteins and thus provoke
wall rupture. In particular, retention of neutrophils in the ILT
impairs the ability of mesenchymal cell progenitors to colonize the
thrombus, thus inhibiting the endogenous healing process.53 Cysteine
proteases are also potent elastolytic and collagenolytic enzymes
associated with AAA development. Several cathepsins42,58,59 and did-
peptidyl peptidase I60 have been reported to be elevated in AAA
tissue, in association with a decrease in their cystatin inhibitors.
5.3 Medial destruction
Lopez-Candales et al. demonstrated that medial smooth muscle cell
density was decreased in human AAA tissues, associated with evi-
dence of smooth muscle cell apoptosis.61 These data have been
largely confirmed,62,63 including reports of accelerated replicative
senescence in cultured smooth muscle cells from AAAs.64
Figure 2 Biological features of the outer media and adventitia in human aneurysm of the abdominal aorta (AAA). (A) General view of the outer part
of an AAA showing the inner ILT, the remaining media (difficult to delimit exactly in the absence of elastic laminae), and the highly vascularized outer
adventitia, containing well-organized inflammatory granuloma (haematoxylin and eosin, ×4). (B) Cholesterol crystal clefts in the outer media (haema-
toxylin and eosin, ×10). (C ) Granuloma can be easily identified as adventitial tertiary lymphoid organs by their high density of B lymphocytes (CD 20
immunostaining, ×4). (D ) Presence of a high density of phagocytosed haemosiderin mainly in the outer part of the media (Perls blue staining, ×4),
providing evidence of convection towards the adventitia of haem released by the ILT.
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The mediators responsible for medial degradation could either be
conveyed from outside to inside by centripetal angiogenesis or from
inside to outside by centrifugal mass transport. Centripetal angiogen-
esis is the main means of leucocyte extravasation from neo-capillaries
into the aortic medial and adventitial tissues. Nevertheless, in the
context of AAA, proteases generated by, stored and conveyed by
the ILT are predominant.
The site of final adventitial rupture is characterized by a high level of
protease expression65 and an important enrichment in leucocytes and
focal neovascularization.66
5.4 Adventitial response
The adventitia reacts to the centrifugal insults by generating angio-
genic, immuno-inflammatory, and fibrotic responses. Depending on
the stage of AAA evolution, the immuno-inflammatory response
includes accumulation of varying numbers of macrophages in the
inner part of the adventitia, capable of phagocytosing iron originating
from ILT haemoglobin, and adventitial tertiary lymphoid organ for-
mation, providing evidence of the shift from innate to adaptive immu-
nity (Figure 2). The adventitia can also be the site of an important
fibroblastic reaction, probably driven by transforming growth
factor-b, leading to collagen accumulation, thus delaying the risk of
rupture.
Neo-angiogenesis in the outer part of the AAA was described
15 years ago.67 A strong spatial correlation between neo-capillaries,
degradation of elastic fibres, and the extent of leucocyte infiltrate in
the outer aortic wall of AAAs has been observed.68 However, in con-
trast to haemorragic plaques or occlusive thrombus, neo-vessels
remain localized in the adventitia and the outer part of the media,
but do not invade the ILT in large AAAs, probably because of an
excess of local proteolytic activity.53
The main early function of macrophages in the AAA adventitia is
probably phagocytosis. This is easily observed by Prussian blue stain-
ing of haemosiderin in macrophages of the outer media or inner
adventitia, providing evidence of the convection of RBC degradation
products from the luminal thrombus to the adventitia.
The observation of chronic peri-aortic infiltrates, consisting mainly
of lymphocytes, monocytes, plasma cells, and sparse mast cells,
usually on a background of fibrous tissue,69 has prompted use of
the term ‘inflammatory AAA’ and retroperitoneal fibrosis70 as a dis-
tinct clinical entity, and the concept of an adventitial shift from innate
to adaptive immunity in AAAs. Koch et al.71 observed that the adven-
titia in AAAs was enriched with lymphoid aggregates containing den-
dritic cells and activated endothelium.72 The similarity with lymphoid
germinal centres has led to the proposal that lymphoid neogenesis
takes place in the AAA adventitia.73 Attempts were then made to
characterize the lymphocyte populations74 and to evaluate
T-helper 1–T-hleper-2 balance,75 presence of B cells,76 and clonal-
ity77 but the neo-antigens, generated by the active thrombus and/
or the degraded media and involved in this shift, remain to be
identified.
Mast cells are tissue-resident leucocytes related to allergic reaction,
including oedema, due to IgE–antigen interactions, leading to degra-
nulation. Mast cells have numerous granules that contain chymases,
and tryptase, histamine, growth factors, and cytokines, partly secreted
in complexes with proteoglycans.78 Chymases and tryptase could act
directly on the matrix but could also activate MMPs, degrade
adhesion molecules,79 or activate the renin–angiotensin system.80
The role of mast cells in AAAs has been suggested in experimental
transgenic mouse models.81 Mast cells, present in the outer media
and adventitia of human AAAs,82 were reported to correlate with
AAA diameter83 and the presence of an ILT, and to be in close associ-
ation with adventitial angiogenesis.84 Since ‘inflammatory AAA’ has
been recently shown to be related to high circulating levels of IgG4
and IgE,85 the relationship between secreted immuglobulins, the pres-
ence of adventitial mast cells, and inflammatory AAA remains to be
established.
Fibroblasts play a critical role in the adventitial response to injury.
They can proliferate and secrete procollagen-1, leading to perivascular
fibrosis and resistance to rupture. Transforming growth factor-b, syn-
thesized by polarized M2 macrophages and immune cells, is probably
the main molecular link between inflammation and the peri-aortic
fibrotic healing process.86 Pathogenic fibrosis of the adjacent retro-
peritoneum and rigid adherence to adjacent structures is usually
observed in association with inflammatory AAAs.87
5.5 Possible involvement of weak
pathogens
The clinical acceleration of AAA growth, the enrichment of ILT by
neutrophils, and the potential impact of doxycycline,88 suggest the
involvement of exogenous weak pathogens.
The first one to be explored in AAA was Chlamydia pneumoniae,89
infection by which could directly90 or indirectly (via lipopolysacchar-
ides91 or antibodies92) contribute to AAA progression. However,
the impact of C. pneumoniae on AAA progression remains highly
controversial.
Recently bacterial DNA of Porphyromonas gingivalis (periodontal) and
Streptococcusmutans (cariogen) have been identified in AAA tissue.93– 95
Nevertheless, the results obtained with polymerase chain reaction
technologies may be skewed by methodological contaminants.96 Oral
bacteria are commensal or weak pathogens, but able to interact directly
with activated platelets,97 making the ILT a privileged site for bacterial
adhesion during transitory bacteraemia, without proliferation and poss-
ible phagocytosis by neutrophils.98 The interactions between coagu-
lation, neutrophils, and bacterial retention have been recently
emphasized in a model of blood clotting in mice.54
Periondotal disease has been epidemiologically linked to athero-
thrombotic clinical events.99 However, epidemiological data linking
periodontal diseases and AAA are currently lacking.
6. Applications to diagnosis
Available molecular diagnostic tools are directly linked to the spatio-
temporal pathophysiology of AAA as described above, and include
circulating biomarkers and functional and molecular imaging.
6.1 Biomarkers
Circulating biomarkers of AAA have been recently reviewed.100,101 In
terms of pathophysiology, circulating biomarkers can be classified in
relation to ILT activities, extracellular matrix degradation in the wall,
and adventitial immuno-inflammatory response. The discovery of
new circulating biomarkers can be driven by pathophysiological
knowledge or approached by modern open technologies, such as
proteomics.102
The earliest biomarkers were directly related to extracellular
matrix proteolysis. Serum elastin peptides and amino terminal pro-
peptide of type III procollagen have been shown to be elevated in
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plasma of AAA patients,103 but with a relatively low sensitivity and
specificity.104 Therefore, direct measurements of proteolytic
enzymes have been used. Circulating plasmin–anti-plasmin com-
plexes105 are particularly sensitive in AAA, associated or not with
fibrin degradation products.106 It has been recently reported that
plasmin–anti-plasmin and D-dimers107 were correlated with aortic
diameter, ILT thickness, aneurysmal growth, and also with decreased
pulmonary function108 in patients with AAA.109,110
Since numerous neutrophils are trapped within the ILT, several cir-
culating markers of neutrophil activation (elastase–a1-antitrypsin
complexes,14 myeloperoxidase, a-defensin) are increased in
AAA.111 Moreover, a1-antitrypsin associated with circulating high-
density lipoprotein is decreased in plasma of patients with AAA,16
providing evidence of its excess consumption. In a similar way, the
plasma level of cystatin C, an inhibitor of cysteine proteases, is
decreased in inverse relation to AAA dimensions.112 In particular,
MMP-9113 or MMP-9–neutrophil gelatinase-associated lipocalin (and
MMP-8) plasma levels could be used for monitoring treatment
efficiency.114
Circulating markers of platelet activation are also increased in
AAA,40 as are circulating plasma thrombin–antithrombin com-
plexes.40 The simultaneous association of increased biomarkers of
both coagulation and fibrinolysis in AAA patients provides evidence
of the biological activity of the ILT.109,110 However, circulating
markers of oxidative stress remain to be identified and validated in
AAAs.
Circulating inflammatory biomarkers and markers of the shift from
innate to adaptive immunity are elevated in patients with AAA. Plasma
inflammatory cytokines,115 such as interferon-g, tumour necrosis
factor-a,116 interleukin-6, and C-reactive protein,117 are all elevated
in the plasma of AAA patients, providing evidence of an inflammatory
process associated with AAA development.
Chlamydia pneumoniae antibodies in serum of AAA patients have
been searched for with variable success,118 questioning the specificity
of this analysis.119 More interesting is the detection of elevated levels
of IgG4 and IgE in the serum of patients with inflammatory AAA.85
The IgG4 syndrome is reported to be associated with an active sclero-
tic process,120 and the IgE syndrome with a different aneurysmal
localization.121
6.2 Imaging
Besides the technological progress, new knowledge in tissue biology
has an impact on the evolution of imaging from simply viewing mor-
phology to detecting function, and on the development of new mol-
ecular imaging of biological processes. This progress not only impacts
the pathophysiology of the disease but could also provide surrogate
markers of therapeutic efficiency.
6.2.1 Calcifications
Calcifications, easily identifiable by X-ray, the oldest method for
visualizing AAAs, are common features in AAA and are not
devoid of biological significance. Hydroxyapatite precipitation in
soft tissue is linked to cell death and membrane particle formation
and binding to the extracellular matrix. In AAA, calcifications are
usually localized in the outer part of the media, thus delimiting
the external side of the aneurysmal dilatation. Lindholt et al. have
recently reported a protective effect of calcification in the evolution
of AAA,122 probably linked to the greater resistance of calcified
tissue to proteolysis.
6.2.2 Bleeding into the ILT
This was initially named the ‘crescent sign’, and it is caused by contrast
medium entering the ILT. High attenuation within the ILT, detected by
ultrasonography and computed tomography scan, was reported
early,123 and correlated with ‘liquefaction’ of the thrombus, providing
evidence of mechanical failure of the ILT when exposed to a pulsatile
load.124 Subsequently, this crescent sign in the ILT was suggested to
signal an impending risk of rupture.125,126
6.2.3 Iron oxide contrast in magnetic resonance imaging
The ILT-trapped RBCs release paramagnetic iron from haem that
causes signal loss in magnetic resonance imaging. Nevertheless, spon-
taneous signal loss obtained using conventional approaches may lack
sensitivity and specificity. Therefore, imaging of iron phagocytic
activity could be enhanced by injections of exogenous iron particle
contrast agents, such small paramagnetic iron oxide.127 Using this
technique, both luminal and adventitial iron phagocytosis, by neutro-
phils and macrophages, respectively, have been identified by magnetic
resonance imaging.
6.2.4 Platelet activation in scintigraphy
Annexin-V binds specifically, with nanomolar affinity, to phosphatidyl-
serine, which is exposed on the surface of activated platelets and
apoptotic cells. Therefore, radiolabelled 99mTc-annexin-V has been
used for assessing the renewal activity of the ILT in an in vivo exper-
imental model of AAA, and ex vivo in human ILT.128 A form for
human use is now under development, which should soon be vali-
dated in clinical investigations.
6.2.5 18-FDG PET scan
Positron emission tomography (PET) studies are usually performed
using 18-fluorodeoxyglucose (FDG) as radiotracer, which reflects
glucose uptake depending on cell metabolic activity. Modern hybrid
scanners are coupled with morphological computed tomography or
with magnetic resonance imaging for attenuation correction and ana-
tomical mapping.
Sakalihasan et al.129 have investigated by PET the increased metab-
olism of an expanding AAA and/or one threatening rupture and
observed, in some cases, an association between 18-FDG uptake by
the aneurysm wall and a rapid expansion of the aneurysm. The
18-FDG was usually observed in the outer part of the AAA wall
and thus probably reflects the presence of a high density of active leu-
cocytes in the adventitia.130 These preliminary observations were
recently confirmed.131 However, in accordance with the reports of
Sakalihasan129 and Truijers,132 no correlation between maximal stan-
dard uptake value and maximal cross-sectional infrarenal AAA diam-
eter was found. Recently, Xu et al. observed an association between
high wall stress and increased metabolic activity in aneurysmal wall
evaluated by PET–computed tomography.133 Therefore, this
method constitutes a new tool for exploring some aspects of wall
biology in AAAs.
7. Therapeutic implications
Apart from surgical or endovascular interventional therapeutics for
large aneurysms, and control of cardiovascular risk factors, including
smoking cessation, the development of specific medical treatment
able to limit aneurysmal growth, or even to induce regression,
remains an unattained challenge. This challenge is particularly
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important in the context of screening programmes aimed at detecting
asymptomatic small aneurysms. Experimental pharmacological134 and
clinical medical135 treatments of AAA have been recently reviewed,
including statins.136 In a recent complement, doxycycline has been
reported to decrease AAA wall infiltration by neutrophils and lym-
phocytes.88,137 An annual 4 week treatment by roxithromycin has
been reported to significantly inhibit AAA growth rate,138,139 but ran-
domized trials with large numbers of patients and long follow-up are
now necessary.
Since ILT renewal associated with AAA progression could be a
therapeutic target, the ability of platelet inhibition to prevent
growth of aneurysms was tested experimentally.140 This hypothesis
was then tested through an observational study in patients with
small AAAs. Treatment of patients with aspirin delayed AAA
growth and reduced the number of cases of interventional thera-
peutics.141 This beneficial effect has been recently confirmed in
another observational study,118 but not by the UK study.142 Never-
theless, as for other medical approaches, a prospective interventional
assay is needed.
Since angiotensin II has been demonstrated to be possibly involved
in experimental aneurysm in apoE – /– mice,143 the effects of renin–
angiotensin system inhibition on AAA progression have been
evaluated in observational case–control studies. The first Canadian
study reported that angiotensin-converting enzyme inhibitors
decreased the risk of rupture,144 whereas the UK AAA screening pro-
gramme showed an increased growth rate associated with
angiotensin-converting enzyme inhibitors.142 This observation under-
scores the urgent need for prospective randomized trials.
8. Conclusions: aneurysm of the
abdominal aorta, a spatiotemporal
model of atherothrombosis
There is now observational evidence that the intraluminal,
haemoglobin-rich thrombus, together with the adventitial angio-
genic145 and immune responses, play important roles in the evolution
of atherothrombosis from the initial stages to clinical complications
(Figure 3). Therefore, AAA represents a unique, well-organized,
spatiotemporal model of human atherothrombosis, associating all
the tissue, cell, and molecular components of the pathology, offering
a unique opportunity to decipher the pathophysiology of human
atherothrombosis and to develop new concepts, as well as future
diagnostic and therapeutic tools.
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